M&T Bank
TVTX icon

M&T Bank’s Travere Therapeutics TVTX Stock Holding History

M&T Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680K Buy
11,962
+992
+9% +$44K ﹤0.01% 1075
2026
Q1 		$326K Sell
10,970
-712
-6% -$21.3K ﹤0.01% 1336
2025
Q4 		$446K Buy
+11,682
New +$380K ﹤0.01% 1189

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

M&T Bank's TVTX Position: Q2 2026 in Review

M&T Bank increased its Travere Therapeutics (TVTX) stake by 9% in Q2 2026, buying an estimated $44K and bringing the position to 11,962 shares worth $680K. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

M&T Bank first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • M&T Bank held 11,962 shares of Travere Therapeutics worth $680K as of Q2 2026.
  • M&T Bank bought 992 Travere Therapeutics shares in Q2 2026, an estimated $44K.
  • Travere Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1075 holding.
  • M&T Bank first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.